Open an account

NeOnc Technologies Holdings

NTHI · NASDAQ

$2.77+$0.05 (+1.84%)TodayMarket closed ·
Prev close $2.72

About NTHI

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Calabasas, California and currently employs 5 full-time employees. The company went IPO on 2025-03-26. The firm is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. The company is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company is developing novel drug delivery methods to be used in combination with novel drug candidates. The firm has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).

Employees
5
Headquarters
Calabasas, California
Listed
Mar 26, 2025
Sector
Health Care
Industry
Pharmaceuticals
Website
neonc.com

NTHI key statistics

Market cap
79.79M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
153.82K
Volume
102.35K
Open price
$2.77
High today
$2.93
Low today
$2.75
52 Week high
$12.00
52 Week low
$2.50

NeOnc Technologies Holdings (NTHI) at a glance

NeOnc Technologies Holdings (NTHI) last traded at $2.77, with a market cap of 79.79M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.75 and $2.93. The current price is 0.7% above the day's low and 5.5% below its high.

Volume so far is 102.35K shares, below the average of 153.82K shares a day.

Over the past year NeOnc Technologies Holdings has ranged from $2.50 to $12.00, and now sits 3% of the way up that range.

NeOnc Technologies Holdings met or beat analyst EPS estimates in 0 of the last 3 quarters. In Q2 FY26 it reported -$0.58 per share against an estimate of -$0.1556.

The average analyst price target is $16.67, 501.7% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $16.67
Low
$13.13
Now
$2.77
High
$21.00

NTHI earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 3 quarters.

  1. Q4 FY25: reported -$0.73 per share against an estimate of -$0.3774
  2. Q1 FY26: reported -$0.35 per share against an estimate of -$0.2244
  3. Q2 FY26: reported -$0.58 per share against an estimate of -$0.1556

NTHI news

  • Press releaseGlobe Newswire

    Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season

  • Press releaseGlobe Newswire

    NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone

  • Press releaseGlobe Newswire

    From Shaq to Musk: The Power Appointment Effect

  • Press releaseGlobe Newswire

    UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances

  • Press releaseGlobe Newswire

    NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development

  • Press releaseGlobe Newswire

    2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope

  • Press releaseGlobe Newswire

    NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer

  • Press releaseGlobe Newswire

    NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt

Similar companies

Companies in the same industry as NeOnc Technologies Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.